※HEPTARES Business Development: The scope of the opportunity using the Heptares approach extends well beyond our growing pipeline.
※Pfizer(10 Target), ※ORBIT(New R&D Initiative), ※Cryo-EM Consortium(Drug Discovery), ※Allergan(M Series), ※Kymab(mAbs), ※leadXpro(Powerful New Approaches)
HTL9936(M1) Estimated Study Completion Date: 9936-103 NCT02546310(September 2016), 9936-104 NCT02710188(September 2016, Primary: August),
HTL18318(M1 oral compounds): 18318-101 NTR5648 & 18318-102 NTR5781, M4, Dual M1/M4, HTL1071(AZD4635): NCT02740985, CGRP(Teva),
HTL14242(mGlu5), Orexin OX1(NIDA), Orexin OX2(Narcolepsy), HTL6641(Dual Orexin), GLP-1(Hyperinsulinism), PAR2(mAbs), ・・・
Utibron & Seebri U.S.(Pre-launch), SO-1105(Preparations for approval application), QVM149(Asthma): NCT02571777, ・・・
※Modelling the ligand binding kinetics in GPCRs (Collaboration with UCL and Heptares): This 4 year PhD research project, start at the end of Sep 2016.
※JITSUBO 採用情報を更新: 原薬プロセス開発研究員、創薬研究員。 ※品質保証責任者(部長ポジション)追加 (8/1)
※HEPTARES Careers: We are seeking a research scientist or senior scientist with a background in organic or analytical chemistry GPCR. (8/22)
※HEPTARES Careers: We now recruit a DMPK Project Leader. work directly with a network of external DMPK suppliers (CROs) and consultants. (8/31)
※MRC LMB Job: Recruitment, Postdoctoral Scientist - Structural Studies GPCRs. Heptares-funded Postdoctoral Scientist position is available. (9/1)
※HEPTARES Careers: Financial Accountant (8/4), Chemistry Senior Scientist (8/11). ※”Recruiting End” (9/5)
※HEPTARES Careers: We are seeking an enthusiastic and motivated HR Administrator. to a new role, working in a small HR team. (9/5)
※Novartis版: "Combined with its safety profile, supports Ultibro Breezhaler as a suitable Steroid-Free treatment option for COPD patients at risk of exacerbation." (9/3)
※SOSEI版:「ウルティブロ ブリーズヘラー」のCOPD増悪抑制が、様々な患者群において、 サルメテロール／フルチカゾンを一貫して上回ることを確認。(9/5)
※Vectura版: "Combined with the existing efficacy and safety profile of Ultibro Breezhaler further confirms our confidence in its outlook." (9/5)
※Drug Profile: Research programme: GPCR modulators - AstraZeneca/ Heptares Therapeutics. (9/6 update)
Alternative Names: CNS therapeutics - AstraZeneca/ Heptaris Therapeutics
Mechanism of Action: G protein-coupled receptor modulators; PAR 2 receptor antagonists
※Drug Profile: Research programme: GPCR modulators - Heptares Therapeutics/ Novartis. (9/6 update)
・06 Sep 2016, No development reported for Undefined indication in United Kingdom (Parenteral)
※Drug Profile: Research programme: GPCR modulators - Heptares Therapeutics/Takeda. (9/6 update)
・06 Sep 2016, No development reported for CNS disorders in United Kingdom (Parenteral)
※Vectura: Novartis has confirmed it will update the market on its plans for Utibron Neohaler and Seebri Neohaler in the US in Q3 2016. (9/7)
※Drug Profile: Research programme: GPCR modulators - Heptares Therapeutics. (9/7 update)
・07 Sep 2016, Early research in Atopic dermatitis in United Kingdom (unspecified route) before September 2016 (Heptares Therapeutics pipeline, September 2016)
・06 Sep 2016, Preclinical trials in Obsessive-compulsive disorders in United Kingdom (unspecified route)
次なる飛躍へ。順調な進捗と共に更なる成長の黎明期にて育ちゆく相場。控える材料と共に水準訂正。笑。
予定されていた業績の急成長と共に更なる成長戦略が始動。R&DやPL等の進捗・拡大の加速が始まる。笑。
※HEPTARES Business Development: The scope of the opportunity using the Heptares approach extends well beyond our growing pipeline.
※Pfizer(10 Target), ※ORBIT(New R&D Initiative), ※Cryo-EM Consortium(Drug Discovery), ※Allergan(M Series), ※Kymab(mAbs), ※leadXpro(Powerful New Approaches)
HTL9936(M1) Estimated Study Completion Date: 9936-103 NCT02546310(September 2016), 9936-104 NCT02710188(September 2016, Primary: August),
HTL18318(M1 oral compounds): 18318-101 NTR5648 & 18318-102 NTR5781, M4, Dual M1/M4, HTL1071(AZD4635): NCT02740985, CGRP(Teva),
HTL14242(mGlu5), Orexin OX1(NIDA), Orexin OX2(Narcolepsy), HTL6641(Dual Orexin), GLP-1(Hyperinsulinism), PAR2(mAbs), ・・・
Utibron & Seebri U.S.(Pre-launch), SO-1105(Preparations for approval application), QVM149(Asthma): NCT02571777, ・・・
※Modelling the ligand binding kinetics in GPCRs (Collaboration with UCL and Heptares): This 4 year PhD research project, start at the end of Sep 2016.
※JITSUBO 採用情報を更新: 原薬プロセス開発研究員、創薬研究員。 ※品質保証責任者(部長ポジション)追加 (8/1)
※HEPTARES Careers: We are seeking a research scientist or senior scientist with a background in organic or analytical chemistry GPCR. (8/22)
※HEPTARES Careers: We now recruit a DMPK Project Leader. work directly with a network of external DMPK suppliers (CROs) and consultants. (8/31)
※MRC LMB Job: Recruitment, Postdoctoral Scientist - Structural Studies GPCRs. Heptares-funded Postdoctoral Scientist position is available. (9/1)
※HEPTARES Careers: Financial Accountant (8/4), Chemistry Senior Scientist (8/11). ※”Recruiting End” (9/5)
※HEPTARES Careers: We are seeking an enthusiastic and motivated HR Administrator. to a new role, working in a small HR team. (9/5)
※Novartis版: "Combined with its safety profile, supports Ultibro Breezhaler as a suitable Steroid-Free treatment option for COPD patients at risk of exacerbation." (9/3)
※SOSEI版:「ウルティブロ ブリーズヘラー」のCOPD増悪抑制が、様々な患者群において、 サルメテロール／フルチカゾンを一貫して上回ることを確認。(9/5)
※Vectura版: "Combined with the existing efficacy and safety profile of Ultibro Breezhaler further confirms our confidence in its outlook." (9/5)
(※Trial Profile: HTL18318-102 (8/23 update) ※Trial Profile: AZD4635 (9/2 update))
※Drug Profile: Research programme: GPCR modulators - AstraZeneca/ Heptares Therapeutics. (9/6 update)
Alternative Names: CNS therapeutics - AstraZeneca/ Heptaris Therapeutics
Mechanism of Action: G protein-coupled receptor modulators; PAR 2 receptor antagonists
※Drug Profile: Research programme: GPCR modulators - Heptares Therapeutics/ Novartis. (9/6 update)
・06 Sep 2016, No development reported for Undefined indication in United Kingdom (Parenteral)
※Drug Profile: Research programme: GPCR modulators - Heptares Therapeutics/Takeda. (9/6 update)
・06 Sep 2016, No development reported for CNS disorders in United Kingdom (Parenteral)
※【四季報先取り新興株５０】そーせいグループ (9/7)
【一時金】期初に子会社ヘプタレスがアラガン社と共同開発契約し一時金１３５億円計上。
アストラゼネカのマイルストーン上乗せ。ノバルティスのロイヤルティも堅調。研究開発費増でも支援金受領で、大幅増益。
【設 立】再生医療開発企業を対象とする投資ファンド設立。
口腔咽頭カンジダ症治療薬の国内臨床３相終了、承認申請準備へ（富士フイルムファーマと独占販売契約）。
【最新の業績予想】
中2016.09(予)売上高16,600 営業利益13,000 経常利益13,500 当期利益11,500 1株益680.7
※Vectura: Novartis has confirmed it will update the market on its plans for Utibron Neohaler and Seebri Neohaler in the US in Q3 2016. (9/7)
※Drug Profile: Research programme: GPCR modulators - Heptares Therapeutics. (9/7 update)
・07 Sep 2016, Early research in Atopic dermatitis in United Kingdom (unspecified route) before September 2016 (Heptares Therapeutics pipeline, September 2016)
・06 Sep 2016, Preclinical trials in Obsessive-compulsive disorders in United Kingdom (unspecified route)
※SOSEIの成長相場の動向
上抜け圏での時間軸調整は良好。笑。日柄調整も順調。笑。予定通りの勘所局面。笑。今回も楽しくなりましたね。笑。
ttp://www.4-traders.com/SOSEI-GROUP-CORPORATION-6814799/charts/&applet_mode=statique
9/_7 (終値17840) 5日線乖離(+5.45％) 25日線乖離(+5.80％) 75日線乖離(+1.59％) 200日線乖離(+15.43％)
次なる展開・進捗も楽しみですね。笑。躍進の年のSOSEIの成長相場を楽しみましょう。笑。